Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

Finasteride can cause lasting sexual and mood issues even after stopping the drug.

Herbal drugs show promise for treating alopecia with fewer side effects, but standardization is challenging.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

Finasteride temporarily suppresses brain activity, but some effects last even after stopping.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

Finasteride and dutasteride do not significantly change beard thickness in men.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Men taking dutasteride may have a higher risk of age-related macular degeneration.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.

The seed extract of Lepidium sativum L. can potentially treat hair loss, showing effects similar to 5% minoxidil.

5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

Combining low-dose dutasteride with finasteride improved a man's hair loss.

Neurosteroids help control dopamine responses in the brain.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.

Dutasteride is effective for treating hair loss.